Chất ức chế BTK

IL-16 Production as a Mechanism of Resistance to BTK Inhibitors and R-CHOP in B-Cell Lymphomas: Mechanistic Insights and Therapeutic Implications

By MedXY 09/12/2026

This review synthesizes evidence on IL-16-driven resistance to BTK inhibitors and chemoimmunotherapy in B-cell lymphomas, highlighting the IL-16/CD9/PI3K axis as a targetable epigenetically regulated survival pathway overcoming drug resistance.

Hematology-Oncology news

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia

By MedXY 02/18/2026

A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradication of minimal residual disease.

Neurology news Rheumatology

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial

By MedXY 12/23/2025

The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 weeks.